<DOC>
	<DOC>NCT00002336</DOC>
	<brief_summary>To determine whether clarithromycin is safe and effective in preventing disseminated Mycobacterium avium Complex in HIV-infected patients with CD4 counts &lt;= 100 cells/mm3.</brief_summary>
	<brief_title>The Safety and Effectiveness of Clarithromycin in the Prevention of Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Inclusion Criteria Patients must have: HIV infection. CD4 count &lt;= 100 cells/mm3. No evidence of MAC. Life expectancy of at least 6 months. Exclusion Criteria Concurrent Medication: Excluded: Certain restricted drugs (details not available). Patients with the following prior conditions are excluded: History of allergy or hypersensitivity to macrolides. Active substance abuse or other conditions that would affect study compliance.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Mycobacterium avium-intracellular Infection</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Clarithromycin</keyword>
</DOC>